AMP functionalized curdlan nanoparticles as a siRNA carrier: Synthesis, characterization and targeted delivery via adenosine A2B receptor

Bao, Qingming; Ganbold, Tsogzolmaa; Qiburi, Qiburi; Bao, Mingming; Han, Shuqin; Baigude, Huricha

doi:10.1016/j.ijbiomac.2021.10.138

Cited by 11 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, we demonstrated that ligand-functionalized LNPs or polymeric NPs can deliver siRNA across the BBB to specific glial cells and regulate their polarization in a mouse stroke model. , We also discovered that adenosine receptors (ARs) can be utilized for the receptor-mediated siRNA delivery to the cells that express ARs including astrocytes and tumor cells. , The LNP is composed of adenosine-functionalized lipid (Ad4-DoGo4) specifically targeting astrocytes in a mouse TBI model . In this study, we first synthesized a multivalent mannose-conjugated lipid (denoted by Man4-DoGo4) (Scheme , Supporting Information, Figure A, Figures S1 and S2) for targeted siRNA delivery to microglia that display cell surface mannose receptors in mouse TBI models.…”

Section: Resultsmentioning

confidence: 99%

Synthesis of Lipidated Ligands and Formulation of Glia-Specific LNPs for RNAi-Mediated BBB Protection

Xiao,

Bao,

Bai

et al. 2024

J. Med. Chem.

Self Cite

View full text Add to dashboard Cite

Pro-inflammatory polarization of microglia and astrocytes results in neuroinflammation and blood−brain barrier (BBB) disruption after a primary traumatic brain injury (TBI). Herein, we demonstrate that the dualligand functionalized lipid nanoparticles (AM31 LNPs) were actively and specifically internalized by microglia and astrocytes via mannose receptor (MR)-and adenosine receptor (AR)-mediated endocytosis, respectively, in a mouse model of TBI. Systemic administration of AM31 LNPs carrying siRNA against p65 resulted in internalization by the glial cells in the peri-infarct region and a robust knockdown of p65 at both mRNA and protein levels in these cells, leading to significant down-regulation of key pro-inflammatory cytokines and up-regulation of key anti-inflammatory cytokines. AM31 LNP-mediated silencing of p65 ameliorated TBI-induced BBB disruption. Our data proved that AM 31 LNP is a promising vehicle for RNA therapeutics for targeting microglia and astrocytes in neural disorder.

show abstract

Section: Resultsmentioning

confidence: 99%

Synthesis of Lipidated Ligands and Formulation of Glia-Specific LNPs for RNAi-Mediated BBB Protection

Xiao,

Bao,

Bai

et al. 2024

J. Med. Chem.

Self Cite

View full text Add to dashboard Cite

show abstract

“…232 It is worth mentioning that endocytosis is an energy-dependent mechanism 304 and that modification of nanoparticles with ligands leads to receptor-mediated endocytosis. 307 Although surface modification of nanostructures is important for their endocytosis in breast tumor cells, 308 it should be noted that after the introduction of nanomaterials to biological medium, proteins are absorbed into surface of nanoparticles and form a biomolecular corona that can affect the fate of nanocarriers. However, studies related to protein corona are limited to in vitro, and a few experiments have focused on impact of protein corona on fate of nanostructures in vivo, but it is still a problem to reveal how protein corona can affect nanoparticle fate.…”

Section: Surface Modificationmentioning

confidence: 99%

“…These nanoparticles internalized into breast tumor cells via receptor‐mediated endocytosis 232 . It is worth mentioning that endocytosis is an energy‐dependent mechanism 304 and that modification of nanoparticles with ligands leads to receptor‐mediated endocytosis 307 . Although surface modification of nanostructures is important for their endocytosis in breast tumor cells, 308 it should be noted that after the introduction of nanomaterials to biological medium, proteins are absorbed into surface of nanoparticles and form a biomolecular corona that can affect the fate of nanocarriers.…”

Section: Surface Modificationmentioning

confidence: 99%

(Nano)platforms in breast cancer therapy: Drug/gene delivery, advanced nanocarriers and immunotherapy

Ashrafizadeh

Zarrabi

Bigham

et al. 2023

Medicinal Research Reviews

View full text Add to dashboard Cite

Breast cancer is the most malignant tumor in women, and there is no absolute cure for it. Although treatment modalities including surgery, chemotherapy, and radiotherapy are utilized for breast cancer, it is still a life‐threatening disease for humans. Nanomedicine has provided a new opportunity in breast cancer treatment, which is the focus of the current study. The nanocarriers deliver chemotherapeutic agents and natural products, both of which increase cytotoxicity against breast tumor cells and prevent the development of drug resistance. The efficacy of gene therapy is boosted by nanoparticles and the delivery of CRISPR/Cas9, Noncoding RNAs, and RNAi, promoting their potential for gene expression regulation. The drug and gene codelivery by nanoparticles can exert a synergistic impact on breast tumors and enhance cellular uptake via endocytosis. Nanostructures are able to induce photothermal and photodynamic therapy for breast tumor ablation via cell death induction. The nanoparticles can provide tumor microenvironment remodeling and repolarization of macrophages for antitumor immunity. The stimuli‐responsive nanocarriers, including pH‐, redox‐, and light‐sensitive, can mediate targeted suppression of breast tumors. Besides, nanoparticles can provide a diagnosis of breast cancer and detect biomarkers. Various kinds of nanoparticles have been employed for breast cancer therapy, including carbon‐, lipid‐, polymeric‐ and metal‐based nanostructures, which are different in terms of biocompatibility and delivery efficiency.

show abstract

“…Hence, insects represent a rich source for the discovery of new AMPs. Many studies have confirmed the biological functions of AMPs, such as their anticancer (Bao et al, 2021;Timmons and Hewage, 2022), antiviral (Liu R. et al, 2022;Nabeta et al, 2022;Nikyar et al, 2022), antibacterial (Maleki Dizaj et al, 2022;Wang et al, 2022b) and immunoregulatory activities (Liu et al, 2018;. There are also some reports on the anti-C. albicans activity of AMPs (Hu et al, 2022;Nabeta et al, 2022;Peng-Wei et al, 2022).…”

Section: Introductionmentioning

confidence: 97%

Heterologous expression of the insect SVWC peptide WHIS1 inhibits Candida albicans invasion into A549 and HeLa epithelial cells

Chen,

Huang,

Yao

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

Candida albicans (C. albicans), a microbe commonly isolated from Candida vaginitis patients with vaginal tract infections, transforms from yeast to hyphae and produces many toxins, adhesins, and invasins, as well as C. albicans biofilms resistant to antifungal antibiotic treatment. Effective agents against this pathogen are urgently needed. Antimicrobial peptides (AMPs) have been used to cure inflammation and infectious diseases. In this study, we isolated whole housefly larvae insect SVWC peptide 1 (WHIS1), a novel insect single von Willebrand factor C-domain protein (SVWC) peptide from whole housefly larvae. The expression pattern of WHIS1 showed a response to the stimulation of C. albicans. In contrast to other SVWC members, which function as antiviral peptides, interferon (IFN) analogs or pathogen recognition receptors (PRRs), which are the prokaryotically expressed MdWHIS1 protein, inhibit the growth of C. albicans. Eukaryotic heterologous expression of WHIS1 inhibited C. albicans invasion into A549 and HeLa cells. The heterologous expression of WHIS1 clearly inhibited hyphal formation both extracellularly and intracellularly. Furthermore, the mechanism of WHIS1 has demonstrated that it downregulates all key hyphal formation factors (ALS1, ALS3, ALS5, ECE1, HWP1, HGC1, EFG1, and ZAP1) both extracellularly and intracellularly. These data showed that heterologously expressed WHIS1 inhibits C. albicans invasion into epithelial cells by affecting hyphal formation and adhesion factor-related gene expression. These findings provide new potential drug candidates for treating C. albicans infection.

show abstract

AMP functionalized curdlan nanoparticles as a siRNA carrier: Synthesis, characterization and targeted delivery via adenosine A2B receptor

Cited by 11 publications

References 37 publications

Synthesis of Lipidated Ligands and Formulation of Glia-Specific LNPs for RNAi-Mediated BBB Protection

Synthesis of Lipidated Ligands and Formulation of Glia-Specific LNPs for RNAi-Mediated BBB Protection

(Nano)platforms in breast cancer therapy: Drug/gene delivery, advanced nanocarriers and immunotherapy

Heterologous expression of the insect SVWC peptide WHIS1 inhibits Candida albicans invasion into A549 and HeLa epithelial cells

Contact Info

Product

Resources

About